22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
IPO Year:
Exchange: AMEX
Website: xxiicentury.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2022 | $5.00 | Buy | Alliance Global Partners |
| 6/15/2022 | $5.00 | Buy | Craig Hallum |
| 3/8/2022 | $6.00 | Buy | Roth Capital |
| 7/23/2021 | $5.00 | Outperform | Cowen |
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt
MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1February 18, 2025 9:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to the
MOCKSVILLE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, (the "Company") is pleased to announce that Larry Firestone, Chief Executive Officer, will present at the Emerging Growth Conference on Wednesday, February 19, 2025, at 10:50 am Eastern Time. Mr. Firestone will provide an overview presentation and may subsequently open the floor for questions. Questions may be submitted in advance to [email protected]. Investors can register in advance to attend the conference and receive any updates at: https
MOCKSVILLE, N.C., Jan. 27, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it has received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the Nasdaq Minimum Bid Price Requirement for continued listing pursuant to Nasdaq Listing Rule 5550(a)(2). Larry Firestone, Chief Executive Officer said, "We are pleased to regain full compliance with the Nasdaq listing standards, an important benefit to our stockholders. We remain committed to our business o
New FDA Rule Cites Extensive Research Using 22nd Century Manufactured Products and Specifically Cites 22nd Century VLN Sales Activity Proposed Standard Designates VLNC as a New Product Category, 22nd Century Ready to Manufacture as Needed to Quickly Expand Commercialization and Distribution FDA Expects Proposed Product Standard Would Significantly Reduce the Morbidity and Mortality Caused by Smoking MOCKSVILLE, N.C., Jan. 15, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today heralded the publication of a proposed new Tobacc
VLN Reduced Nicotine Content Cigarettes from 22nd Century Is the Only Authorized Combustible Solution to Support the FDA's War on Smoking MOCKSVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, was featured today in a Washington Post news story (https://www.washingtonpost.com/health/2025/01/14/cigarettes-low-nicotine-regulation-biden/) addressing new federal policy activities that could reduce the health harms of smoking. The article focuses on a recent U.S. Food and Drug Administration policy proposal to mand
FDA Reduced Nicotine Content Proposal Indicated to Have Completed OMB Review as of January 3, 2025 FDA Spokesperson Indicates Policy Could Be Among Most Impactful Population-Level Actions in the History of U.S. Tobacco Product Regulation MOCKSVILLE, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it stands ready to support the U.S. Food and Drug Administration's proposed tobacco product standard to mandate reduced nicotine content in cigarettes, which is indicated to have cleared review by th
Agreement covers 11 existing brands, supports launch 8 additional premium brands with Smoker Friendly retail and dealer locations Creates foundation to launch additional reduced nicotine content brands in 2025 MOCKSVILLE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced the completion of a new license and manufacturing agreement with Smoker Friendly, one of the largest independent cigarette retailers in the United States. The agreement includes 11 SF brands currently sold in the Smoker Friendly net
Mocksville, North Carolina--(Newsfile Corp. - December 13, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it will effect a reverse stock split of its outstanding shares of common stock, par value $0.00001 per share (the "Common Stock"), at a ratio of 1-for-135, to be effective as of December 17, 2024. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on Nasdaq.Lawrence Firestone, Chief Executive Officer said,
Recent FDA Action Advances Policy Proposal That Originated During First Trump Administration and Continued to Progress Under Biden AdministrationMocksville, North Carolina--(Newsfile Corp. - December 12, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it applauds action by the U.S. Food and Drug Administration to advance its long-standing proposal mandating a drastic reduction in the amount of nicotine in cigarettes, a cornerstone goal of public health experts seeking to reduce the harms of smoking. "We are excited to see defin
SCHEDULE 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)
S-3/A - 22nd Century Group, Inc. (0001347858) (Filer)
S-3 - 22nd Century Group, Inc. (0001347858) (Filer)
S-8 - 22nd Century Group, Inc. (0001347858) (Filer)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
8-K - 22nd Century Group, Inc. (0001347858) (Filer)
Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00
Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00
Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00
Cowen initiated coverage of 22nd Century Group with a rating of Outperform and set a new price target of $5.00
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)
Remains on Path to Cash Positive Operations in Q1 2025Commencing Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple CategoriesMocksville, North Carolina--(Newsfile Corp. - November 12, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the third quarter ended September 30, 2024, and provided an update on recent business highlights.Third Quarter 2024 Financial Results (compared to Second Quarter 2024, except as noted)All figures reported below reflect continuing operations, excludin
Third quarter 2023 net revenue of $17.8 millionExpanded VLN® availability to more than 4,550 stores in 19 statesProposed FDA menthol ban regulation now undergoing review at OMBGVB bulk ingredient volume of 49,000 kg shippedInitiated over $15 million in annualized operating cost reductionsReduced principal debt balances by $8.1 million in October 2023 BUFFALO, N.Y., Nov. 06, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today reported results for the third quarter ended September 30, 2023, and provi
Second Quarter 2023 Net Revenues Increased 62% to $23.4 MillionLaunched VLN® Sales in California, Texas and FloridaDelivered Record GVB Ingredient Volumes as Dominant Supplier in North AmericaInitiated Operating Cost Reduction Program Targeting $15+ Million in Annualized SavingsUpdated 2023 Revenue Outlook to a Range of $80 Million to $90 Million to Reflect Revised VLN® Rollout Timelines and Transitioning GVB Ingredient Volumes Back to Internal Production BUFFALO, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco,
Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA 1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and Nutraceuticals Markets BUFFALO, NY, Jan. 24, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the acquisition of privately held RX Pharmatech Ltd (RXP), a leading United Kingdom distributor of cannabinoids with 1,276 novel food applications with the U.K. Food Standards Agency (FSA). Terms of the agreement include an up-front paymen
BUFFALO, N.Y., Oct. 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, will release third quarter 2022 financial results on Tuesday, November 8, 2022, at 6:00 a.m. ET. In conjunction with the news release, 22nd Century Group will host a conference call at 10:00 a.m. ET on the same day. During the webcast, James A. Mish, chief executive officer, John Miller, president of 22nd Century's tobacco business, and Hugh Kinsman, chief financial officer, will provide an update on the Company and review third quarter 2022 res
Provides Transformational Platform to Rapidly Grow Hemp/Cannabis FranchiseTransaction Immediately Accretive and Will Double Company's Total RevenueAdds Significant Commercial Scale to Existing Hemp/Cannabis FranchiseGVB Biopharma has Achieved Strong Growth and Leading Market Share in Hemp-Derived Active Ingredients BUFFALO, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the acquisition of privately held GVB Biopharma. As a contract development and manufacturing organization (CD
BUFFALO, N.Y., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science, today announced entry into the global specialty hops market, its third and newest plant franchise. The Company released an update letter to shareholders from CEO James A. Mish describing its opportunities and plans in this market. The Company also posted an overview deck describing its entry into the hops market in the Investor Relations section of the corporate website at www.xxiicentury.com/investors. Dear Fellow Shareholders, Following the exciting progress in our tobacco
Initiated International Launch Process For VLN®, First Sales Planned by First Quarter 2022First Revenue From Hemp/Cannabis Franchise to Commence in Second Half of 2021Third Plant-Based Franchise to be Introduced on August 30, 2021Uplisting common shares to the Nasdaq Capital Market ("Nasdaq") and will continue to trade under current symbol, "XXII"Record Second Quarter Net Sales of $8.4 Million, Up Greater Than 30% From the Second Quarter of 2020Executing From a Strong Financial Position with Cash and Cash Equivalents of $62.3 Million as of June 30, 2021. BUFFALO, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII), a leading plant-based biotechnology com
3 - 22nd Century Group, Inc. (0001347858) (Issuer)
3 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
3 - 22nd Century Group, Inc. (0001347858) (Issuer)
3 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
4 - 22nd Century Group, Inc. (0001347858) (Issuer)
3 - 22nd Century Group, Inc. (0001347858) (Issuer)
3 - 22nd Century Group, Inc. (0001347858) (Issuer)
Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO
BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e
CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022. "The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hugh's success at GVB by elevating his financial lea
Further Enhances 22nd Century Group's Deep Expertise in Plant-Based Biotechnology BUFFALO, N.Y., April 11, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced the appointment of Dr. Calvin Treat as Chief Scientific Officer, effective May 23, 2022. In this new role, Dr. Treat will lead the expanding scientific, research and technological operations of the company, leveraging its expertise, IP, and partnerships across all three of its alkaloid plant franchises toward becoming a global leader in specia
Carmines has submitted hundreds of PMTAs to the FDA and spearheaded the successful MRTPA submitted by 22nd Century Group (NASDAQ:XXII) that won an FDA marketing order in December 2021.COSTA MESA, CA / ACCESSWIRE / March 2, 2022 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium, nicotine-based, e-cigarette space, today announced the appointment of Edward Carmines, Ph.D., to its Board of Directors. Dr. Carmines is an accomplished scientist and regulatory affairs expert with extensive experience working with the Center for Tobacco Products at the U.S. Food and Drug Administration ("FDA"). In addition to an extraordinary record of success w
FDA's Rulemaking Process Could Make VLN® Menthol King Reduced Nicotine Cigarettes the Only Menthol Cigarette on the Market Opportunity to Accelerate FDA's Plan to Cap Nicotine in Cigarettes at Levels Already Achieved in 22nd Century's VLN® Products BUFFALO, N.Y., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, congratulates Dr. Robert Califf on his confirmation as FDA Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Califf is known to be a longtime proponent of innovative tobacco
BUFFALO, N.Y, Jan. 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced the appointment of James A. Mish to its Board of Directors (Board). The addition of Mr. Mish, who currently serves as Chief Executive Officer at 22nd Century, significantly enhances the Board's depth of experience in the commercialization of science-driven consumer products as the Company prepares to launch its first reduced nicotine content tobacco products and commercially modified hemp/cannabis plant lines. "Th
Visionary in the Fields of Biotechnology and Genomics to Extend Broad Expertise to Company's Strategy, Technology Development, Commercialization, and Value Creation Efforts BUFFALO, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced the appointment of Anthony Johnson to its Board of Directors. Mr. Johnson is an accomplished life sciences and biotechnology executive leader with broad expertise in corporate strategy, technology development, marketing, and business development. Mr. Johnson will serve as a member of
To Date, 22nd Century Has Provided More Than 31 Million Variable Nicotine Content Research Cigarettes for Numerous Independent Scientific Studies Research on Nicotine Content Reduction in Cigarettes Underpins the FDA's Proposed Mandate to Reduce Nicotine Levels in All Cigarettes Sold in the U.S. to "Minimally or Non-Addictive" Levels, a Feat Already Achieved by VLN® Delivery of Research Cigarettes is to Support Nicotine Cap Mandate and is Unrelated to 22nd Century's Modified Risk Tobacco Product (MRTP) Application for VLN® Cigarettes BUFFALO, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII), a leading plant-based, biotechnology company that is focused on to
22nd Century’s Proprietary VLN® King and VLN® Menthol King Poised to Play a Central Role in Making FDA’s Reduced Nicotine Mandate FeasibleMRTP Authorization of VLN® King and VLN® Menthol King Will Serve as a Major Catalyst for the FDA to Accelerate RuleContaining 95% Less Nicotine than Traditional Cigarettes, VLN® is the Only Combustible Tobacco Product that Complies with the FDA’s Proposed Nicotine Cap WILLIAMSVILLE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it continues
For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second